Background
Gilead Sciences develops and sells prescription medications, including the HIV drug Biktarvy, in domestic and foreign markets. After a Maryland patient received Turkish-market Biktarvy through his employer’s self-funded health plan, Gilead investigated and found that RX Valet, Advanced Pharmacy, Affordable RX Meds, and Gregory Santulli had arranged for hundreds of bottles of foreign-market Gilead drugs to be shipped to U.S. patients. Although the Turkish Biktarvy was manufactured with Gilead’s authorization and chemically identical to the U.S. version, its labeling and patient information were in Turkish and omitted warnings and other information accompanying U.S.-market Biktarvy.
Gilead sued the four direct participants, along with third-party administrator Meritain Health and pharmacy benefit manager ProAct. It alleged that the first group directly infringed Gilead’s trademarks by importing and distributing materially different foreign-market drugs, while Meritain and ProAct contributorily infringed by supplying data, claims-processing, patient-referral, and payment services despite knowing or having reason to know of the infringement. The District of Maryland entered a preliminary injunction barring the defendants from importing, advertising, selling, or facilitating the importation of products bearing specified Gilead marks.
The Court’s Holding
The Fourth Circuit affirmed. It adopted the material-differences doctrine for gray-market goods and held that Gilead was likely to show that the imported medications were not genuine for Lanham Act purposes. The foreign-market drugs materially differed from the authorized U.S. versions because their labels and accompanying materials used foreign languages and omitted warnings, prescribing information, National Drug Code numbers, and other disclosures relevant to consumers. They also bypassed Gilead’s domestic quality controls governing temperature monitoring, chain-of-custody documentation, recalls, and authorized distribution. Chemical identity alone did not make the drugs genuine, and the first-sale doctrine therefore did not defeat Gilead’s claims.
The court also held that Gilead was likely to establish contributory infringement by Meritain and ProAct. Under the Fourth Circuit’s application of Inwood, prior specific notice from the trademark owner is not required: liability may arise when a service provider continues supplying services to identified infringers whom it knows or has reason to know are infringing. The record supported findings that Meritain and ProAct knew or should have known both that they were facilitating international sourcing of Gilead-branded drugs and that the imported products differed materially from U.S. versions. The court declined to add “degree of control” as a separate element of contributory infringement. It also held that the FDCA did not preclude Gilead’s Lanham Act claims because deciding material differences did not require interpreting or enforcing FDA regulations.
The court found no abuse of discretion on the remaining preliminary-injunction factors. Gilead received a statutory presumption of irreparable harm, and its ten-month investigation before filing suit did not rebut that presumption. The district court permissibly concluded that potential harm to Gilead’s goodwill and reputation, the balance of equities, and the public interest favored preliminary relief. The Fourth Circuit declined to exercise pendent appellate jurisdiction over the denial of Santulli’s personal-jurisdiction motion and held that he had not preserved his separate argument concerning the jurisdictional showing required for preliminary relief.
Key Takeaways
- Foreign-market goods bearing authentic trademarks may still be non-genuine under the Lanham Act when they materially differ from authorized U.S. goods or bypass the trademark owner’s legitimate quality-control system.
- For prescription drugs, foreign-language labeling, omitted safety information, missing product identifiers, and differences in distribution safeguards can be material even when the medication is chemically identical.
- Contributory trademark liability does not require prior specific notice from the trademark owner or a separate showing that a service provider controlled the means of infringement; knowledge or reason to know under Inwood is sufficient.
Why It Matters
The decision establishes Fourth Circuit law governing gray-market products and confirms that packaging, safety information, and distribution controls can determine whether authentic goods are “genuine” for trademark purposes. The ruling is especially significant for alternative prescription-drug funding programs because importing lower-cost foreign versions may create Lanham Act exposure even when the manufacturer made the drugs and their formulations match U.S. products.
The opinion also clarifies the exposure of intermediaries. Administrators, pharmacy benefit managers, and other service providers may face contributory liability when their data, referral, payment, or processing services facilitate known infringement, without first receiving a cease-and-desist letter or other specific notice from the trademark owner.